References
- Van-der-Noll R, Leijen S, Neuteboom GH, et al. Effect of inhibition of the FGFR-MAPK signaling pathway on the development of ocular toxicities. Cancer Treat Rev 2013;39:664–72
- Guagnano V, Furet P, Spanka C, et al. Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ 398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J Med Chem 2011;54:7066–83
- Takeuchi K, Ito F. Receptor tyrosine kinases and targeted cancer therapeutics. Biol Pharm Bull 2011;34:1774–80
- Kottakis F, Polytarchou C, Foltopoulou P, et al. FGF-2 regulates cell proliferation, migration, and angiogenesis through an NDY1/KDM2B-miR- 101-EZH2 pathway. Mol Cell 2011;43:285–98
- Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010;10:116–29
- Gangjee A, Zhao Y, Raghavan S, et al. Design, synthesis and evaluation of 2-amino-4-m-bromoanilino-6-arylmethyl-7H-pyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors and antiangiogenic agents. Bioorg Med Chem 2010;18:5261–73
- Chen Z, Wang X, Zhu W, et al. Acenaphtho[1,2-b]pyrrole-based selective fibroblast growth factor receptors 1 (FGFR1) inhibitors: design, synthesis, and biological activity. J Med Chem 2011;54:3732–45
- Yang F, Zhang Y, Ressler SJ, et al. FGFR1 is essential for prostate cancer progression and metastasis. Cancer Res 2013;73:3716–24
- Weiss J, Sos ML, Seidel D, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010;2:62–93
- Turner N, Pearson A, Sharpe R, et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 2010;70:2085–94
- Liang G, Chen G, Wei X, et al. Small molecule inhibition of fibroblast growth factor receptors in cancer. Cytokine Growth Factor Rev 2013;24:467–75
- Ravindranathan KP, Mandiyan V, Ekkati AR, et al. Discovery of novel fibroblast growth factor receptor 1 kinase inhibitors by structure-based virtual screening. J Med Chem 2010;53:1662–72
- Fearon AE, Gould CR, Grose RP. Int. FGFR signalling in women's cancers. J Biochem Cell Biol 2013;45:2832–42
- Dokduang H, Juntana S, Techasen A, et al. Survey of activated kinase proteins reveals potential targets for cholangiocarcinoma treatment. Tumour Biol 2013;34:3519–28
- Byron SA, Chen H, Wortmann A, et al. The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors. Neoplasia 2013;15:975–88
- Patel A, Tiwari AK, Chufan EE, et al. PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells. Cancer Chemother Pharmacol 2013;72:189–99
- Gryshchenko AA, Levchenko KV, Bdzhola VG, et al. Design, synthesis and biological evaluation of naphthostyril derivatives as novel protein kinase FGFR1 inhibitors. J Enzyme Inhib Med Chem 2014;18:1–7
- Skaper SD, Kee WJ, Facci L, et al. The FGFR1 inhibitor PD 173074 selectively and potently antagonizes FGF-2 neurotrophic and neurotropic effects. Neurochem 2000;75:1520–7
- Mohammadi M, McMahon G, Sun L, et al. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science 1997;276:955–60
- Thompson AM, Delaney AM, Hamby JM, et al. Synthesis and structure–activity relationships of soluble 7-substituted 3-(3,5-dim-ethoxyphenyl)-1,6-naphthyridin-2-amines and related ureas as dual inhibitors of the fibroblast growth factor receptor-1 and vascular endothelial growth factor receptor-2 tyrosine kinases. J Med Chem 2005;48:4628–53
- Grand EK, Chase AJ, Heath C, et al. Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074. Leukemia 2004;18:962–6
- Wang Y, Cai Y, Ji J, et al. Discovery and identification of new non-ATP competitive FGFR1 inhibitors with therapeutic potential on non-small-cell lung cancer. Cancer Lett 2014;344:82–9
- Kumar SB, Narasu L, Gundla R, Dayam R, JARPS. Fibroblast growth factor receptor inhibitors. Curr Pharm Des 2013;19:687–701
- Yang J, Zhao H, Xin Y, Fan L. MicroRNA-198 inhibits proliferation and induces apoptosis of lung cancer cells via targeting FGFR1. J Cell Biochem 2014;115:987–95
- Wu X, Huang H, Wang C, et al. Identification of a novel peptide that blocks basic fibroblast growth factor-mediated cell proliferation. Oncotarget 2013;4:1819–28